Clinical Genetics

Cover image for Vol. 92 Issue 6

Edited By: Reiner A. Veitia

Impact Factor: 3.326

ISI Journal Citation Reports © Ranking: 2016: 63/167 (Genetics & Heredity)

Online ISSN: 1399-0004



Author Guidelines


Sections

1. Submission
2. Aims and Scope
3. Manuscript Categories and Requirements
4. Preparing the Submission
5. Editorial Policies and Ethical Considerations
6. Author Licensing
7. Publication Process After Acceptance
8. Post Publication
9. Editorial Office Contact Details
10. Production Office Contact Details

1. SUBMISSION

Authors should kindly note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium.

Once the submission materials have been prepared in accordance with the Author Guidelines, manuscripts should be submitted online at http://mc.manuscriptcentral.com/cge

The submission system will prompt authors to use an ORCID iD (a unique author identifier) to help distinguish their work from that of other researchers. Click here to find out more.

Click here for more details on how to use ScholarOne.

For help with submissions, please contact: cge-office@wiley.com

Guidelines for Cover Submissions

If you would like to send suggestions for artwork related to your manuscript to be considered to appear on the cover of the journal, please follow these general guidelines.

2. AIMS AND SCOPE

Clinical Genetics links research to the clinic, translating advances in our understanding of the molecular basis of genetic disease for the practising clinical geneticist. The journal publishes high quality research papers, short reports, and reviews that connect medical genetics research with clinical practice.

Topics of particular interest are:

  • Linking genetic variations to disease
  • Genome rearrangements and disease
  • Epigenetics and disease
  • The translation of genotype to phenotype
  • Genetics of complex disease
  • Management/intervention of genetic diseases
  • Novel therapies for genetic diseases
  • Developmental biology, as it relates to clinical genetics
  • Cancer Genetics
  • Genome-wide analyses (genomics, transcriptomics, epigenomics) with an obvious significance for the clinic
  • Studies of animal models that help understand the genetic basis of human disease
  • Bioinformatics and computational analysis of genetic/genomic disorders
  • Ethical, legal and social implications of medical genetics
  • Social science research on the psychological and behavioural aspects of living with or being at risk of genetic disease
  • Teaching medical and clinical genetics (concepts and resources).

3. MANUSCRIPT CATEGORIES AND REQUIREMENTS

i. Original Articles

Contributions intended for publication as an Original Article should be so labelled.
Word limit: 6,000 words maximum, including title page, abstract, references, figure legends and Acknowledgements.
Figures/Tables: Total of no more than to seven figures and/or tables.
Description: Original Articles feature novel findings and developments. We particularly welcome articles providing evidence of novel gene discoveries, or describing research about the second confirming mutation for a novel gene, especially if they provide functional data or mechanistic insights.

ii. Short Reports

Contributions intended for publication as Short Reports should be so labelled.
Word limit: 2,500 words maximum, including title page, abstract, references, figure legends and Acknowledgements.
Figures/Tables: Total of no more than three figures and/or tables.
Description: Short Reports present definitive findings, molecular analyses of collected case reports, or single case reports of unusual clinical or scientific importance. Reports must be self-contained pieces, and those describing a single variant at a well-known locus will be published only if they are of unusual interest or if functional data incriminating the variant are provided. The format of Short Reports should be identical to Original Articles but in some circumstances the main body of the text can be presented without division into sections. This section is suitable for Exome/Whole genome sequence (WGS) reports incriminating novel variants in human disease. A description containing numerical details about the number of reads and the number and type of variants observed should be included. Reports on potentially damaging isolated variants without strong arguments incriminating them as causal defects will be given low priority. A VCF file must be provided as supplementary material (maximum size – 100000 kb). The authors must deposit the phenotypic data in PhenomeCentral.

iii. Letters to the Editor

Word limit: 900 words maximum, including title page, 5 references, a figure legend and Acknowledgements.
Letters are not subdivided into sections nor do they include an abstract or online supplements. They can include for-review-only supplements.
Figures/Tables: Total of no more than one figure or table.
References: Maximum of 5 references (included in the word count).
Description: Letters describing new findings are no longer accepted as Initial Submissions. Letters are a suitable venue for reporting interesting observations that, in the opinion of the Editors and referees do not warrant publication as Short Reports.

iv. Correspondence

Word limit: 300 words maximum
Description: This section is appropriate for publication of readers' correspondence regarding any article published in Clinical Genetics. The authors of the article in question will be invited to respond. Please note that this is done prior to acceptance. A Correspondence will only be published if deemed to be of interest to our readership and of a sufficient scientific standard. Due to tremendous space constraints on the journal, we can only publish approximately 20 percent of the submissions.

v. Mini-reviews and Reviews

Word limit: 3,000 words maximum (Mini-reviews) and 7,500 words maximum (Reviews), including title page, abstract, references, figure legends and Acknowledgements.
Figures/Tables: Total of no more than 4 figures and/or tables (Mini-reviews) or 7 figures and/or tables (Reviews). Meta-analyses and systematic reviews of observational studies should comply with PRISMA guidelines.
Description: This section highlights current developments in relevant areas of medical genetics. Mini-reviews and Reviews are invited and their publication free of charge, but you can send a pre-submission inquiry (including a cover letter, an abstract and an outline of the main sections) to the Editor-in-Chief (reiner.veitia@ijm.fr) if you are interested in submitting to this section. Online supplements are accepted for Review Articles; these should be uploaded as separate Supplementary files.

vi. Announcements

Announcements are published free of charge. Announcements must be received 8 weeks before the month of the issue in which publication is desired. Announcements may be submitted by e-mail to the Editorial office at CGE-office@wiley.com for approval.

4. PREPARING THE SUBMISSION

Initial Submission

Submit "Your paper your way". Occasionally the editors may ask you to modify the format of your paper before proceeding. Only when your paper is at the revision stage will you be requested to put it in the final intended format. However, for clarity, initial submissions should be divided into sections as described below (see Parts of the Manuscript). Moreover, Clinical Genetics requires that all appropriate steps be taken in obtaining informed consent of any and all human subjects participating in the research and a relevant statement must be included in the Materials and Methods section of the manuscript at the initial submission. A statement indicating that the procedures employed were reviewed and approved by the appropriate institutional review committee is also required (see more details below). If your submission contains any identifiable patient images or other protected health information, you must provide documented permission from the patient (or the patient’s parent or legal representative) before review. The documented permission may be supplied as supplemental material uploaded with the submission.

Cover Letters

Include a letter from the author who will be responsible for correspondence regarding the manuscript as well as for communications among authors regarding revisions and approval of proofs.

The letter should include:

  • an outline of the main findings and why Clinical Genetics would be interested in publishing them (first documented disease-causing variant, first confirmatory study, analyses of large series of patients or variants, etc.)
  • any information needed to ensure a fair review process, including related manuscripts submitted to other journals

Parts of the Manuscript

The manuscript should be submitted in separate files: main text file; figures.

Main Text File

The text file should be presented in the following order:

i. A short informative title that contains the major key words. The title should not contain abbreviations (see Wiley's best practice SEO tips);
ii. A short running title of less than 40 characters;
iii. The full names of the authors;
iv. The author's institutional affiliations where the work was conducted, with a footnote for the author’s present address if different from where the work was conducted;
v. Acknowledgments;
vi. Abstract and keywords;
vii. Main text;
viii. References;
ix. Tables (each table complete with title and footnotes);
x. Figure legends;
xi. Appendices (if relevant).

Figures and supporting information should be supplied as separate files.

Authorship

Please refer to the journal’s authorship policy the Editorial Policies and Ethical Considerations section for details on eligibility for author listing.

Acknowledgments

Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section. Financial and material support should also be mentioned. Thanks to anonymous reviewers are not appropriate.

Conflict of Interest Statement

Authors will be asked to provide a conflict of interest statement during the submission process. For details on what to include in this section, see the section ‘Conflict of Interest’ in the Editorial Policies and Ethical Considerations section below. Submitting authors should ensure they liaise with all co-authors to confirm agreement with the final statement.

Abstract

Please provide an unstructured abstract of no more than 200 words.

Keywords

Please provide four to nine keywords. Keywords should be taken from those recommended by the US National Library of Medicine's Medical Subject Headings (MeSH) browser list at www.nlm.nih.gov/mesh.

Main Text

Please divide the main text into the following sections: Introduction; Materials and Methods; Results; Discussion.

References

All references should be numbered consecutively in order of appearance and should be as complete as possible. In text citations should cite references in consecutive order using Arabic superscript numerals. For more information about AMA reference style please consult the AMA Manual of Style

Sample references follow:

Journal article
1. King VM, Armstrong DM, Apps R, Trott JR. Numerical aspects of pontine, lateral reticular, and inferior olivary projections to two paravermal cortical zones of the cat cerebellum. J Comp Neurol 1998;390:537-551.

Book
2. Voet D, Voet JG. Biochemistry. New York: John Wiley & Sons; 1990. 1223 p.

Internet document
3. American Cancer Society. Cancer Facts & Figures 2003. http://www.cancer.org/downloads/STT/CAFF2003PWSecured.pdf Accessed March 3, 2003

Tables

Tables should be self-contained and complement, not duplicate, information contained in the text. They should be supplied as editable files, not pasted as images. Legends should be concise but comprehensive – the table, legend, and footnotes must be understandable without reference to the text. All abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. Statistical measures such as SD or SEM should be identified in the headings.

Figure Legends

Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.

Figures

Although authors are encouraged to send the highest-quality figures possible, for peer-review purposes, a wide variety of formats, sizes, and resolutions are accepted. Click here for the basic figure requirements for figures submitted with manuscripts for initial peer review, as well as the more detailed post-acceptance figure requirements.

Figures submitted in colour. Colour figures may be published online free of charge; however, the journal charges for publishing figures in colour in print. If the author supplies colour figures, they will be sent a Colour Work Agreement once the accepted paper moves to the production process. Any article received by Wiley with colour work will not be published until the original form has been returned. Please note that it is preferable that line figures (e.g. graphs and charts) are supplied in black and white so that they are legible if printed by a reader in black and white.

Additional Files

Appendices

Appendices will be published after the references. For submission they should be supplied as separate files but referred to in the text.

Graphical Table of Contents

The journal’s table of contents will be presented in graphical form with a brief abstract.

Please upload the Graphical Abstract as an Image File as the first item in the Manuscript. Please ensure that it is clearly sub-titled ‘Graphical Abstract’. The Graphical Abstract should be designed to be read online in conjunction with the text abstract. It should be approximately square, ideally in colour and should contain a high impact Figure, Graph or Photograph that summarises the key findings of your research. The Graphical Abstract should include text in the form of labels and short phrases. Images of patients’ faces should not be included. As some search engines may not return the Graphical Abstract with the text Abstract; the text Abstract should still be written in a manner that allows it to be understood without reference to the Graphical Abstract.

Supporting Information

Supporting information is information that is not essential to the article, but provides greater depth and background. It is hosted online and appears without editing or typesetting. It may include tables, figures, videos, datasets, etc.

Click here for Wiley’s FAQs on supporting information.

Note: if data, scripts, or other artefacts used to generate the analyses presented in the paper are available via a publicly available data repository, authors should include a reference to the location of the material within their paper.

If you opt for our transparent peer-review you must prepare an online supplementary document containing the referees’ comments (exactly as they appear in the Decision letter), as well as yours point-by-point responses.

General Style Points

The following points provide general advice on formatting and style.

  • Abbreviations: In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Initially, use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation only. For further details, see Units, Symbols, and Abbreviations. A Guide for Medical and Scientific Editors and Authors. (available from The Royal Society of Medicine Press, 1 Wimpole Street, London WIM 8AE, England). Do not use Roman numerals in the text. In decimal fractions, a full stop, and not a comma, must be used. The minus sign is shown as -.
  • Units of measurement: Measurements should be given in SI or SI-derived units. Visit the Bureau International des Poids et Mesures (BIPM) website for more information about SI units
  • Numbers: numbers under 10 are spelt out, except for: measurements with a unit (8mmol/l); age (6 weeks old), or lists with other numbers (11 dogs, 9 cats, 4 gerbils).
  • Trade Names: Chemical substances should be referred to by the generic name only. Trade names should not be used. Drugs should be referred to by their generic names. If proprietary drugs have been used in the study, refer to these by their generic name, mentioning the proprietary name and the name and location of the manufacturer in parentheses.

Wiley Author Resources

Manuscript Preparation Tips: Wiley has a range of resources for authors preparing manuscripts for submission available here. In particular, authors may benefit from referring to Wiley’s best practice tips on Writing for Search Engine Optimization.

Editing, Translation, and Formatting Support: Wiley Editing Services can greatly improve the chances of a manuscript being accepted. Offering expert help in English language editing, translation, manuscript formatting, and figure preparation, Wiley Editing Services ensures that the manuscript is ready for submission.

Video Abstracts

A video abstract can be a quick way to make the message of your research accessible to a much larger audience. Wiley and its partner Research Square offer a service of professionally produced video abstracts, available to authors of articles accepted in this journal. You can learn more about it by clicking here. If you have any questions, please direct them to videoabstracts@wiley.com.

5. EDITORIAL POLICIES AND ETHICAL CONSIDERATIONS

Editorial Review and Acceptance

Clinical Genetics aims to be a leading journal by keeping the reader up-to-date on the latest developments in the field, providing on-line access and publishing research of the highest quality.

The acceptance criteria for all papers are the quality and originality of the research and its significance to journal readership. Manuscripts are single-blind peer reviewed. Papers will only be sent to review if the Editor-in-Chief determines that the paper meets the appropriate quality and relevance requirements.

We are committed to provide a rapid publication of manuscripts. Accepted manuscripts are normally published within 12 weeks after critical review and acceptance.

Fast-track and scoop protection. Clinical Genetics considers fast-track requests on exceptional occasions. Send a pre-submission inquiry to the Editor-in-Chief (CGE-office@wiley.com and reiner.veitia@ijm.fr) including a detailed cover letter explaining your findings and an abstract. You should hear back from us within 4 working days. A decision on publication on the full manuscript will be reached within three weeks. A speedy review does not in any way guarantee acceptance of the manuscript, nor does it imply rapid release if the paper is accepted. However, we offer “scoop protection” meaning that if similar findings are published by others during the revision process, your paper will not be rejected on the grounds that it now lacks novelty.

Optional transparent peer-review. We propose to the authors to make the editorial process transparent for accepted manuscripts by publishing, as an online supplementary document, the referees’ comments directed to the authors, as well as the authors' point-by-point responses. Internal communications between editors and editorial board members will remain excluded from these policies. Referee anonymity will be maintained, unless a referee chooses to sign his or her report.

Wiley's policy on the confidentiality of the review process is available here.

Data Sharing and Data Accessibility

Clinical Genetics expects that data supporting the results in the paper will be archived in an appropriate public repository. Whenever possible the scripts and other artefacts used to generate the analyses presented in the paper should also be publicly archived. Exceptions may be granted at the discretion of the editor for sensitive information such as human subject data or the location of endangered species. Authors are expected to provide a data accessibility statement, including a link to the repository they have used, to accompany their paper.

Human Studies and Subjects

For manuscripts reporting medical studies that involve human participants, a statement identifying the ethics committee that approved the study and confirmation that the study conforms to recognized standards is required, for example: Declaration of Helsinki; US Federal Policy for the Protection of Human Subjects; or European Medicines Agency Guidelines for Good Clinical Practice. It should also state clearly in the text that all persons gave their informed consent prior to their inclusion in the study.

Patient anonymity should be preserved. Photographs need to be cropped sufficiently to prevent human subjects being recognized (or an eye bar should be used). Images and information from individual participants will only be published where the authors have obtained the individual's free prior informed consent. Authors do not need to provide a copy of the consent form to the publisher; however, in signing the author license to publish, authors are required to confirm that consent has been obtained. Wiley has a standard patient consent form available for use.

Animal Studies

A statement indicating that the protocol and procedures employed were ethically reviewed and approved, as well as the name of the body giving approval, must be included in the Methods section of the manuscript. Authors are encouraged to adhere to animal research reporting standards, for example the ARRIVE guidelines for reporting study design and statistical analysis; experimental procedures; experimental animals and housing and husbandry. Authors should also state whether experiments were performed in accordance with relevant institutional and national guidelines for the care and use of laboratory animals:

• US authors should cite compliance with the US National Research Council's Guide for the Care and Use of Laboratory Animals, the US Public Health Service's Policy on Humane Care and Use of Laboratory Animals, and Guide for the Care and Use of Laboratory Animals.
• UK authors should conform to UK legislation under the Animals (Scientific Procedures) Act 1986 Amendment Regulations (SI 2012/3039).
• European authors outside the UK should conform to Directive 2010/63/EU.

Clinical Trial Registration

The journal requires that clinical trials are prospectively registered in a publicly accessible database and clinical trial registration numbers should be included in all papers that report their results. Authors are asked to include the name of the trial register and the clinical trial registration number at the end of the abstract. If the trial is not registered, or was registered retrospectively, the reasons for this should be explained.

Research Reporting Guidelines

Accurate and complete reporting enables readers to fully appraise research, replicate it, and use it. Authors are encouraged to adhere to the recognised research reporting standards of the EQUATOR Network which collects more than 370 reporting guidelines.

Gene Expression Data

Microarray/RNA-Seq data must be submitted to a repository prior to submission. The Accession Number for the dataset(s) must be provided prior to acceptance of the manuscript. If the data are password-protected, the user name and password must be provided in the cover letter of the manuscript at the time of submission.

Species Names

Upon its first use in the title, abstract, and text, the common name of a species should be followed by the scientific name (genus, species, and authority) in parentheses. For well-known species, however, scientific names may be omitted from article titles. If no common name exists in English, only the scientific name should be used.

Genetic Nomenclature

Sequence variants should be described in the text and tables using both DNA and protein designations whenever appropriate. Sequence variant nomenclature must follow the current HGVS guidelines; see varnomen.hgvs.org, where examples of acceptable nomenclature are provided.

Sequence Data

Nucleotide sequence data can be submitted in electronic form to any of the three major collaborative databases: DNA Data Bank of Japan (DDBJ, www.ddbj.nig.ac.jp), EMBL Nucleotide Archive (ebi.ac.uk/ena) or GenBank (www.ncbi.nlm.nih.gov/genbank).

Phenotype

When describing phenotype it is strongly advised to follow HPO terminology (http://www.human-phenotype-ontology.org) or the recommendations outlined in the American Journal of Medical Genetics’ Special Issue: Elements of Morphology: Standard Terminology [ Volume 149A Issue 1, Pages 1 - 127 (January 2009)].

Association Studies

Please note that we do not publish associations unless it is accordance with guidelines by Little et al., J Clin Epidemiol. 2009 Jun;62(6):597-608.e4 [Strengthening the reporting of genetic association studies (STREGA)-an extension of the strengthening the reporting of observational studies in epidemiology (STROBE) statement] and Kraft et. al., Nat Rev Genet. 2009 Apr;10(4):264-9 [Beyond odd ratios- communicating disease risk based on genetic profiles].

Genome Sequence Variants

Because of the importance of the issue and the general consensus on the rules, Clinical Genetics is adopting an editorial policy that requires compliance with the rules to describe chromosomal and gene sequence variants before manuscripts will be accepted and published. When referring to an alteration to the genome, the terms “variant”, “disease-causing variant” or “pathogenic variant” (depending on the nature of the alteration) are preferred to “mutation” (Cutting, 2014, Am J Hum Genet 4:5-10).

Structural variants

Prior to publication, authors with articles describing structural and copy number variants (CNVs), are required to submit all such variants to either the Database of Genomic Variants Archive (DGVa) (http://www.ebi.ac.uk/dgva/) or the Database of Genomic Structural Variation (dbVar) (http://www.ncbi.nlm.nih.gov/dbvar/). Genomic structural variation can be complex to represent, so authors should follow the guidance provided on the GDVa and dbVar sites. If the data include clinical assertions, they should be submitted to ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/), not dbVar. The associated identification numbers should be used to describe the variants in the manuscript. A figure or table that encapsulates the full results of your genome-wide scan must be submitted as well.

Variants affecting individual genes

Authors must ensure that sequence variants in individual genes are correctly described and are deposited into the appropriate Locus Specific Database (LSDB) for the gene or disease of interest prior to acceptance and publication. Variants should be described in the text and tables using both DNA and protein designations whenever appropriate. Variants described only in the context of protein-sequence changes are not acceptable. In compiling variant descriptions, there are several specific issues that need to be addressed:

Gene symbols and OMIM numbers

All manuscripts must include (when available) HGNC-approved gene symbols (http://www.genenames.org/) and OMIM database reference numbers (http://www.omim.org/) for genes and/or disorders. Gene symbols may be requested for loci for which no symbol exists using the Gene symbol request form (http://www.genenames.org/cgi-bin/request). In addition, commonly used alternative gene and disease symbols may also be used in the abstract and as key words. There are separate OMIM numbers for diseases and genes and they are not to be used interchangeably.

Reference sequences

Variants must be reported in the context of a defined reference sequence. Authors should always include the GenBank Accession Number of the relevant reference sequence(s), with version number (e.g., RefSeq NM_123456.3 or GenBank U654321.1), in the Materials and Methods section and as a footnote in tables listing variants. Authors are encouraged to use the Locus Reference Genomic (LRG) reference sequence (http://www.lrg-sequence.org/) which dispenses with the need for sequence versions, if a record exists for the gene in question (e.g., LRG_1).

Variant nomenclature

The most current guidelines are summarized on the Mutation Nomenclature Homepage at the HGVS website (http://www.hgvs.org/mutnomen/). Examples of acceptable nomenclature are also provided. If alternative nomenclature schemes (e.g., for legacy exon- or amino-acid numbering) are commonly found in the literature, they may also be used in addition to approved nomenclature, but they must be defined clearly. Variants may be described using dbSNP identifiers (e.g., rs123456:A>G). Authors should also refer to den Dunnen and Antonarakis, 2000, Hum Mutat 15:7–12 and to den Dunnen and Paalman, 2003, Hum Mutat 22:181-182 for additional information. Complex rearrangements can be described using the HGVS nomenclature (Taschner and den Dunnen, 2011, Hum Mutat 32:507-511) and the nomenclature is being adapted to accommodate the reporting of chromosomal variants detected by several technologies.

Variant checking

Authors are advised to check sequence variant descriptions using the Mutalyzer program (https://mutalyzer.nl/). Using batch mode, several variants can be analysed at once. Please see the article by Wildeman et al., 2008, Hum Mutat 29:6-13 for more information.

Submission of variants to databases

Authors must confirm the status of database submission in their covering letter. In addition, authors should note in the manuscript (e.g., in the methods section) the database(s) to which they have submitted their variants and provide the URL(s). We encourage the use of widely accessible genetics databases as repositories for human gene sequence variation information. Links to gene variant databases can be obtained from the Human Genome Variation Society web site (http://www.hgvs.org/) or using the url "GeneSymbol".lovd.nl (e.g.,http://TP53.lovd.nl).

Conflict of Interest

The journal requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include, but are not limited to: patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker's fees from a company. Please describe the role of the study sponsor(s), if any, in study design; collection; analysis and interpretation of data; writing of the report and in the decision to submit the report for publication. The existence of a conflict of interest does not preclude publication. A conflict of interest statement must be included on the title page and should entail any conflicts that exist for each author, or declare the absence of conflict for each author. If the authors have no conflict of interest to declare, they must also state this at submission. It is the responsibility of the corresponding author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships.

Funding

Authors should list all funding sources in the Acknowledgments section. Authors are responsible for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the correct nomenclature: https://www.crossref.org/services/funder-registry/

Authorship

The list of authors should accurately illustrate who contributed to the work and how. All those listed as authors should qualify for authorship according to the following criteria:

1. Have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data;
2. Been involved in drafting the manuscript or revising it critically for important intellectual content;
3. Given final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content; and
4. Agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section (for example, to recognize contributions from people who provided technical help, collation of data, writing assistance, acquisition of funding, or a department chairperson who provided general support). Prior to submitting the article all authors should agree on the order in which their names will be listed in the manuscript.

Additional Authorship Options. Joint first or senior authorship: In the case of joint first authorship, a footnote should be added to the author listing, e.g. ‘X and Y should be considered joint first author’ or ‘X and Y should be considered joint senior author.’

ORCID

As part of the journal’s commitment to supporting authors at every step of the publishing process, the journal requires the submitting author (only) to provide an ORCID iD when submitting a manuscript. This takes around 2 minutes to complete. Find more information here.

Publication Ethics

This journal is a member of the Committee on Publication Ethics (COPE). Note this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read Wiley'sTop 10 Publishing Ethics Tips for Authors here. Wiley’s Publication Ethics Guidelines can be found here.

Manuscript transfer to Molecular Genetics and Genomic Medicine and Clinical Case Reports

This journal collaborates with two Wiley Open Access journals, Molecular Genetics and Genomic Medicine and Clinical Case Reports, to enable rapid publication of good quality manuscripts that are unable to be accepted for publication by our journal. Authors may be offered the option of having their paper, along with any related peer reviews, automatically transferred for consideration by the Editor of one of the two journals. Authors will not need to reformat or rewrite their manuscript for transferral, and publication decisions will be made a short time after the transfer takes place. For more information please visit the journal homepages by clicking the links above.

6. AUTHOR LICENSING

If your paper is accepted, the author identified as the formal corresponding author will receive an email prompting them to log in to Author Services, where via the Wiley Author Licensing Service (WALS) they will be required to complete a copyright license agreement on behalf of all authors of the paper.

Authors may choose to publish under the terms of the journal’s standard copyright agreement, or OnlineOpen under the terms of a Creative Commons License.

General information regarding licensing and copyright is available here. To review the Creative Commons License options offered under OnlineOpen, please click here. (Note that certain funders mandate that a particular type of CC license has to be used; to check this please click here.)

Self-Archiving definitions and policies. Note that the journal’s standard copyright agreement allows for self-archiving of different versions of the article under specific conditions. Please click here for more detailed information about self-archiving definitions and policies.

Open Access fees: If you choose to publish using OnlineOpen you will be charged a fee. A list of Article Publication Charges for Wiley journals is available here.

Funder Open Access: Please click here for more information on Wiley’s compliance with specific Funder Open Access Policies.

7. PUBLICATION PROCESS AFTER ACCEPTANCE

Accepted article received in production

When an accepted article is received by Wiley’s production team, the corresponding author will receive an email asking them to login or register with Wiley Author Services. The author will be asked to sign a publication license at this point.

Accepted Articles

The journal offers Wiley’s Accepted Articles service for all manuscripts. This service ensures that accepted ‘in press’ manuscripts are published online very soon after acceptance, prior to copy-editing or typesetting. Accepted Articles are published online a few days after final acceptance, appear in PDF format only, are given a Digital Object Identifier (DOI), which allows them to be cited and tracked, and are indexed by PubMed. After publication of the final version article (the article of record), the DOI remains valid and can continue to be used to cite and access the article.

Proofs

Once the paper is typeset, the author will receive an email notification with full instructions on how to provide proof corrections.

Publication Charges

Colour figures. Colour figures may be published online free of charge; however, the journal charges for publishing figures in colour in print. If the author supplies colour figures, they will be sent a Colour Work Agreement once the accepted paper moves to the production process. Any article received by Wiley with colour work will not be published until the original form has been returned. Please note that it is preferable that line figures (e.g. graphs and charts) are supplied in black and white so that they are legible if printed by a reader in black and white.

Early View

The journal offers rapid speed to publication via Wiley’s Early View service. Early View (Online Version of Record) articles are published on Wiley Online Library before inclusion in an issue. Note there may be a delay after corrections are received before the article appears online, as Editors also need to review proofs. Once the article is published on Early View, no further changes to the article are possible. The Early View article is fully citable and carries an online publication date and DOI for citations.

Citing this Article: eLocators

This journal now uses eLocators. eLocators are unique identifies for an article that service the same function page numbers have traditionally served in the print world. When citing this article, please insert the eLocator in place of the page number. For more information, please visit the Author Services eLocator page here.

8. POST PUBLICATION

Access and sharing

When the article is published online:

• The author receives an email alert (if requested).
• The link to the published article can be shared through social media.
• The author will have free access to the paper (after accepting the Terms & Conditions of use, they can view the article).
• The corresponding author and co-authors can nominate up to ten colleagues to receive a publication alert and free online access to the article.

Print copies of the article can now be ordered (instructions are sent at proofing stage or email offprint@cosprinters.com).

Promoting the Article

To find out how to best promote an article, click here.

Measuring the Impact of an Article

Wiley also helps authors measure the impact of their research through specialist partnerships with Kudos and Altmetric.

9. EDITORIAL OFFICE CONTACT DETAILS

For queries about submissions, please contact cge-office@wiley.com

10. PRODUCTION OFFICE CONTACT DETAILS

For any queries regarding your paper post-acceptance, please email the Production Editor at cge@wiley.com

Author Guidelines Updated 29 Sep. 2017

SEARCH

SEARCH BY CITATION